Volume : 11, Issue : 09, September – 2024
Title:
DESIGN AND DEVELOPMENT OF CORE IN-CUP TABLET OF LANSOPRAZOLE
Authors :
M.Divya* and V.Saikishore
Abstract :
In the present study colon targeted core-in-cup tablets of Lansoprazole was designed for effective treatment of inflammatory bowel disease. Colon targeted core-in-cup tablets were prepared in two steps. Core tablets were prepared by wet granulation technique and cup tablets were prepared by direct compression technique . The core tablets were kept in cup tablets and coated by using 10% cellulose acetate phthalate as enteric coating polymer. FTIR study confirmed that there was no interaction between drug and polymer. The core-in-cup tablets were subjected to various evaluation parameters and the results obtained were within the range. In order to simulate the pH changes along the GI tract, three dissolution media with pH 1.2, 7.4 and 6.8 were sequentially used. The dissolution profiles followed zero order kinetics and the mechanism of drug release was governed by peppas model. The diffusion exponent value( n) values were found to be more than 0.5 (n>0.5) , indicted that the drug release was predominantly controlled by non fickian diffusion. The release rate of drug from the core tablets can be governed by the concentration of natural polymer employed in the preparation of tablets. Among all the formulations Lansoprazole tablets prepared with Moringa olifera gum in 1:1 ratios shown controlled drug release for a period of 12 hours. The obtained results revealed the capability of the designed formulation in delaying drug release for a programmable period of time and to show the targeted drug delivery in the colon region for effective treatment of Peptic ulcer
Keywords: Lansoprazole , Biodegradable gums, film coat, core in cup tablet
.
Cite This Article:
Please cite this article in press M.Divya et al., Design And Development Of Core In-Cup Tablet Of Lansoprazole.,Indo Am. J. P. Sci, 2024; 11 (09).
Number of Downloads : 10
References:
1. Amidon, S., Brown, J. E., and Dave, V. S. Colon-targeted oral drug delivery systems: design trends and approaches. AAPS Pharm. Sci. Tech. 2015;16: 731–741.
2 Jadhav J R , Salunkhe K S,. Burute GD, Chaudhar S R. Formulation and evaluation of colonic compression coated tablet of Lansoprazole. Journal of Pharmacy Research. 2012;5(5):2783-2788.
3.Varshosaz, J.; Emami, J.; Trvakoli, N.; Fassihi, A.; Minaiyan, M.; Ahmadi, F.; Dorkoosh, F. Synthesis and evaluation of dextran-Lansoprazole conjugates as colon specific prodrugs for treatment of ulcerative colitis. Int. J. Pharm. 2009;365: 69–76.
4.Dilger K, Alberer M, Busch A, and Gleiter C H. Pharmacokinetics and pharmacodynamic action of Lansoprazole in children with Crohn’s disease, Aliment. Pharmacol. Ther. 2006;.23 : 387–395.
5.Krishnamachari Y, Madan P,Lin S. Development of pH- and time-dependent oral microparticles to optimize Lansoprazole delivery to ileum and colon, Int. J. Pharm. 2007; 29 : 238–47.
6. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci. 2003;6:33–66.
7. Mura P, Maestrelli F, Cirri M, González Rodríguez ML, Rabasco Alvarez AM. Development of entericcoated pectin-based matrix tablets for colonic delivery of theophylline. J Drug Target. 2003;11:365–71.
8.Asghar LF, Azeemuddin M, Jain V, Chandran S. Design and in vitro evaluation of formulations with Ph and transit time controlled sigmoidal release profile for colon-specific delivery. Drug Deliv. 2009;16:205–13.
9. Hoie, O., Wolters, F. L., Riis, L., Bernklev, T., Aamodt, G., Clofent, J. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132;507–515.
10. Qi M, Wang P, Wu D. A novel pH- and time-dependent system for colonic drug delivery. Drug Dev Ind Pharm. 2003; 29:661–7.
11. Jess, T., Riis, L., Vind, I.,Winther, K. V., Borg, S., Binder V. Changes in clinical characteristics, course, and prognosis of Peptic ulcerduring the last 5 decades: a population-based study from Copenhagen,Denmark. Inflamm. Bowel. Dis. 2007; 13: 481–489.
12. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm. 2002;235:1–15.
13. Li, Y. L., Wang, J. Y., Yang, D. B., Dong, M. H., and Tong, Y.Evaluation on preparation process of brevisapin colon-specific tables and its in vitro release. Zhongguo Zhong Yao Za Zhi, 2013;38: 817–820.
14. Obitte, N., Chukwu, A., and Onyishi, I. The use of a pH-dependent and Non pH-dependent natural hydrophobic biopolymer (Landolphia owariensis latex) as capsule coating agents in in vitro controlled release of metronidazole for possible colon targeted delivery. Int. J. Appl. Res. Nat. Products. 2010;3: 1–17.
15. Boyapally H, Nukala RK, Douroumis D. Development and release mechanism of diltiazem HCl prolonged release matrix tablets. Drug Deliv,2009;16:67–74.
16. Kotagale N, Maniyar M, Somvanshi S, Umekar M, Patel CJ. Eudragit-S, Eudragit-L and cellulose acetate phthalate coated polysaccharide tablets for colonic targeted delivery of azathioprine. Pharm Dev Technol. 2010;15(4):431-7.
17. Amrutkar JR, Gattani SG. Chitosan-chondroitin sulfate based matrix tablets for colon specific delivery of indomethacin. AAPS Pharm Sci Tech. 2009;10:670–7.
18. Mundargi RC, Patil SA, Agnihotri SA, Aminabhavi TM.Development of polysaccharide based colon targeted drug delivery systems for the treatment of amoebiasis. Drug Dev Ind Pharm.2007;33:255–64.